Oramed Pharmaceuticals Inc.
ORMP
$2.73
-$0.02-0.73%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 264.20% | 273.88% | 25.00% | 48.07% | -312.97% |
| Total Depreciation and Amortization | 3.33% | 0.00% | -3.23% | -40.38% | -3.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -319.51% | -350.82% | -31.16% | -24.04% | 215.63% |
| Change in Net Operating Assets | 462.94% | -67.66% | -10,593.33% | -99.08% | -25.34% |
| Cash from Operations | 54.03% | -0.45% | -84.14% | 73.09% | -442.05% |
| Capital Expenditure | 100.00% | -33.33% | 72.73% | -120.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 169.94% | -332.22% | 53.02% | 145.06% | -136.19% |
| Cash from Investing | 169.94% | -332.27% | 53.11% | 145.02% | -136.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 2.70% | -- | -- | 7.44% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.70% | -- | -- | 7.44% | 95.77% |
| Foreign Exchange rate Adjustments | -90.00% | 4,100.00% | 50.00% | -166.67% | 175.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 161.96% | -392.19% | 63.17% | 128.88% | -164.45% |